Verastem, Inc.
AVMAPKI FAKZYNJA CO-PACK
KRAS mutant-type (mt) recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Resolved
432days ago
Approval decision · May 1, 2025
What's at stake
A final FDA approval decision on AVMAPKI FAKZYNJA CO-PACK for KRAS mutant-type (mt) recurrent Low-Grade Serous Ovarian Cancer (LGSOC) is expected May 1, 2025.
Primary source
· SEC 8-K
verified 15h ago
“following U.S. FDA approval in May 2025”